13 October 2021 - The EMA has ended the rolling review of CVnCoV, CureVac AG’s COVID-19 vaccine, after the company informed the Agency that it was withdrawing from the process.

Since February 2021, the EMA’s CHMP has been reviewing data on CVnCoV as part of a rolling review, whereby the company submits data as they become available in order to speed up the evaluation of an eventual marketing authorisation application.

Read EMA press release